Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm. (PubMed, Ther Adv Respir Dis) - Oct 11, 2026 - "Mepolizumab (anti-IL-5) reduces exacerbations by 27% (rate ratio 0.73; 95% CI 0.56-0.96) in eosinophilic asthma in children and adolescents aged 6-17 years (MUPPITS-2)...Benralizumab (anti-IL-5Rα) induces near-complete eosinophil depletion with extended every-8-week maintenance dosing; FDA approval was extended to children ≥6 years in April 2024 based on the TATE trial (SIROCCO/CALIMA/BORA/TATE). Safety profiles are generally favourable; dupilumab-associated conjunctivitis and omalizumab-related anaphylaxis require specific monitoring protocols.Biologic therapies have ushered paediatric severe asthma into the precision medicine era. Dupilumab and tezepelumab demonstrate robust efficacy across multiple phenotypes, while biomarker assessment enables rational, individualised selection."
Biomarker • Clinical • HEOR • Journal • Real-world evidence • Review • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Pulmonary Disease • Respiratory Diseases • IL4 • IL5
|